Other than breast and prostate cancer, decreased DAB2IP expression by promoter methylation has been identified in several other malignancies including hepatocellular carcinoma 20, lung cancer 21, and gastrointestinal tumors 22. Here, DAB2IP is linked to hepatocellular carcinoma.